Teva’s Ascent Faces Mounting Skepticism

Pharmaceutical giant Teva is experiencing a remarkable surge in its share price, yet a growing chorus of doubters is emerging just as the stock approaches record levels. While recent regulatory approvals in Europe are fueling the growth narrative, a notable increase in short-selling activity is signaling underlying market concerns.

The company’s trajectory recently encountered a hurdle in the United States. A federal court dismissed Teva’s lawsuit challenging the Medicare drug price negotiation program. The company had contended that the initiative infringed upon its property rights for medications such as Austedo.

Offsetting this legal development, positive research data has emerged. The IMPACT-TD study confirmed the Read more...